Current immunosuppressive approaches in liver transplantation.

Area of Science:

• Immunosuppression
• Transplantation Medicine
• Pharmacology

Background:

• Potent immunosuppressive agents have significantly improved liver transplant (LT) outcomes over two decades.
• Ongoing research seeks optimal immunosuppressive protocols balancing efficacy with minimized drug toxicity.
• Personalized immunosuppression strategies are emerging, considering disease etiology and comorbidities like renal dysfunction.

Purpose of the Study:

• To review current trends in immunosuppressive strategies post-liver transplantation.
• To evaluate the safety and efficacy of specific drug combinations, including steroid minimization and calcineurin inhibitor (CNI) reduction.
• To explore the role of mammalian target of rapamycin (mTOR) inhibitors in LT immunosuppression.

Main Methods:

• Review of studies on immunosuppressive protocols in liver transplantation.
• Analysis of data regarding combined mycophenolate mofetil and minimal dose CNI therapy.
• Examination of research on mTOR inhibitors (sirolimus and everolimus) and their impact on renal function and CNI-related side effects.

Main Results:

• Combined mycophenolate mofetil and minimal CNI dose therapy demonstrates safety and improves renal function and cardiovascular risk.
• Results regarding renal improvement after switching to mTOR inhibitors with CNI reduction are conflicting.
• Sirolimus (SRL) efficacy in improving recurrence-free survival for hepatocellular carcinoma patients post-LT requires further investigation.

Conclusions:

• Tailored immunosuppression, including steroid minimization and CNI reduction, is a key trend in liver transplantation.
• Combined mycophenolate mofetil and reduced CNI doses offer a favorable safety and efficacy profile.
• Further research is needed to clarify the role of mTOR inhibitors in preventing CNI-related nephrotoxicity and improving outcomes in specific patient populations.